Questions List - Hall A

What is your experience with EOE and achalasia overlap (patients who have a typical manometry and typical biopsies) How many require myotomy, what are the treatments they responded to in the EOE levelPosted onJanuary 27, 2021 2:42 pm

do you have any experience with monoclonal antibody rx Posted onJanuary 27, 2021 2:29 pm

Posted onJanuary 27, 2021 2:29 pm

Posted onJanuary 27, 2021 2:29 pm

Posted onJanuary 27, 2021 2:28 pm

is there ever an indication fot oral steroids forv example the patient with complicated stricturesPosted onJanuary 27, 2021 2:24 pm

Posted onJanuary 27, 2021 2:22 pm

Posted onJanuary 27, 2021 2:22 pm

Posted onJanuary 27, 2021 2:22 pm

Posted onJanuary 27, 2021 2:22 pm

Posted onJanuary 27, 2021 2:22 pm

Posted onJanuary 27, 2021 2:22 pm

Posted onJanuary 27, 2021 2:22 pm

Posted onJanuary 27, 2021 2:22 pm

Posted onJanuary 27, 2021 2:22 pm

did she do FLIP testPosted onJanuary 27, 2021 2:17 pm

If a a patients is in remission, when will you consider stopping treatment and just follow up?Posted onJanuary 27, 2021 2:14 pm

patient that tried all 3 therapies and responded only to viscous budesonide. dose lowered to once a day. still in remission clinically and histologically. for how long to continue steroids?Posted onJanuary 27, 2021 2:11 pm

is there an increase in monillia esophagitis with JORVEZA if there is-what do you recommenedPosted onJanuary 27, 2021 2:08 pm

תודה רבה!Posted onJanuary 27, 2021 1:42 pm

זאת לא אמורה להיות המשימה של הדרג המקצועי של משרדי הממשלה?Posted onJanuary 27, 2021 1:32 pm

מי ממן אתכם היום?ישר כחPosted onJanuary 27, 2021 1:23 pm

********** לובי 99 ************Posted onJanuary 27, 2021 12:49 pm

במיון סורוקה היינו קוראים לזה ״טקס הנחת סטטוסקופ״ - לעתים אף בלי להכניס אתו לאוזניים Posted onJanuary 27, 2021 12:46 pm

אחת המשימות של רופא במרפאה היא לצור rapport עם המטופל גם כאשר הבדיקה אינה תורמת לאבחון בעיה ספציפית - היא תורמת רבות ל reassurance וליצירת יחסי חולי-מטופל התקינים גם חיוך ויחס עדיב לא תורמים ישירות לתהליך האבחון - האם נוותר גם עליהם? בכך חשיבותהPosted onJanuary 27, 2021 12:43 pm

אפרת דיברה על נחיצות של בדיקה גופנית להערכת הסיכון ההרדמתי לפני אנדוסקופיה - רעות על משמעות של הבדיקה בבירור מרפאתי. ויהיה ההבדל הקטן. Posted onJanuary 27, 2021 12:37 pm

תומכת מאוד בבדיקה גופנית בקליניקה לפחות בפגישה ראשונה גם אם מדובר בבדיקה לפני קולון סקר. ובהמשך לפי תצורך כמובן. לפחות ב1 אחוז מהחולים מגלים ממצאים שדורשים התיחסות. לצערינו לאחרונה רואים יותר ויותר חולים מופנים ע"י רופא משפחה ובפהניה אין כלל התיחסות לבדיקה גופנית וגם לא לאנמנזה. שווה מחשבה! אם יש בדיקה גופנית רלוונטית בקליניקה אין צורך בבדיקה חוזרת לפני קולונוסקופיה.Posted onJanuary 27, 2021 12:37 pm

... and the outstanding study (with Mamoro Watanabi) on the ability of ulcerative colitis patient-derived organoids to heal and replace colonic mucosal ulcers when given orallyPosted onJanuary 27, 2021 12:21 pm

מעולה!!! Posted onJanuary 27, 2021 11:49 am

What is your take of this study? How are you going to incorporate it into your daily practice? How are you going to address it during the visits?Posted onJanuary 27, 2021 11:45 am

In our previous work we show that one of the important barriers for FOBT-positive “no-showers” - if not the important one - is the fear of already having cancer. They are so convinced they already have cancer – that are scary to take any proactive step that may potentially prove it. I afraid your algorhythm cannot properly address this barrier. What do you say?Posted onJanuary 27, 2021 11:38 am

There are observations that individuals infected with H. pylori (as well as other abundant pathogens, parasites could be another example) are less prone to immune-mediated conditions: asthma, atopic dermatitis, allergies – even IBD. And the hypothesis is – that it may be that the exposure of a developing immune system of a child to a variety of diverse challenges teaches his immune system tolerance. And there is no argument that in some adults, H. pylori could be a foe, but at the same time, in infancy, it is a part of this antigen diversity we all need to create tolerance. If we will not be able to pass all these infections to our children – may them be paying later in life by immune-mediated conditions?Posted onJanuary 27, 2021 11:30 am

Could you please address the cost difference if the screening is performed in a stool antigen test vs UBTPosted onJanuary 27, 2021 11:23 am

My take from Dr. Chang's talk is that it may it happen that PYY an a primarely anti-hyphae antibiotic, that also has some “bring-this-hyphae-less-free-food” signal function (promoting sense of satiety = preventing further food ingestion)?Posted onJanuary 27, 2021 10:55 am

There is no Q&A in this session, unfortunately Posted onJanuary 27, 2021 10:55 am

******* Session 8 ***********Posted onJanuary 27, 2021 10:29 am

Toda raba!Posted onJanuary 27, 2021 10:26 am

אם מביאים בחשבון את העומס הנפשי שכרוך במעקב - האם בטוח שיש מקום למעקב אחר החולים האלה- הרי בסה"כ הפרוגנוזה היא טובהPosted onJanuary 27, 2021 10:25 am

Are we sure that all this patients really suffer from CD? Was this controlled for NSAID's? Aspirin?Posted onJanuary 27, 2021 10:24 am

Should this impact the decision to treat hemorrhoids?Posted onJanuary 27, 2021 10:23 am

Posted onJanuary 27, 2021 10:23 am

did you address the severity of mucosal inflammation severity ?Posted onJanuary 27, 2021 10:22 am

Osteoporosis is a well known complication of terminal ileitis and may occur in otherwise asymptomatic patients. Have you accessed the patient' files for for osteoporosis?Posted onJanuary 27, 2021 10:20 am

עדיין קיימת עיצה להפסיק נוגדי TNF ?לפני הלידה, האם יש מקום לשנות מדניות זוPosted onJanuary 27, 2021 10:14 am

The main objective of mucosal adaptive immunity in neonates is to develop tolerance to abundant harmless (food-bacteria-fungi-protea-etc.) antigens (while the infections in neonates are dealt mainly by innate and not adaptive immunity). How did you study addressed impact of anti-TNFs on tolerance?Posted onJanuary 27, 2021 10:08 am

******Break for Batia **********Posted onJanuary 27, 2021 10:04 am

Internal fistulas frequently develop in the segment immediately proximal to stricture. How the presence of stricture impact your therapeutic decision algorithm?Posted onJanuary 27, 2021 10:00 am

Thank you David for the great talk ! Posted onJanuary 27, 2021 9:42 am

Will a presence of osteoporosis in an asymptomatic and uncomplicated mild Crohn's patient who is otherwise well on "therapeutic diet" (incl. Hb-alb-CRP-calpro) prompt you to start effective anti-inflammatory therapy?Posted onJanuary 27, 2021 9:30 am

We often have hesitations regarding the final diagnosis and I tell my patient that "taking some time" without treatment would not be harmful Am I wrong?Posted onJanuary 27, 2021 9:29 am

Severity - "Not by CDAI alone": The Practice Parameters Committee of the American College of Gastroenterology, “working definitions of Crohn’s activity”: (Am J Gastroenterol. 2009 Feb;104(2):465-83) Mild–moderate disease • Ambulatory • Able to tolerate oral alimentation Moderate–severe disease Failed to respond to treatment, or • Fever • Significant (>10%) weight loss • Abdominal pain or tenderness • Intermittent nausea or vomiting • Significant anemia Severe/fulminant disease Failed to respond to (corticosteroids or biologic) treatment, or • High fevers and systemic toxicity • Persistent vomiting • Intestinal obstruction • Peritoneal signs • Cachexia • Evidence of an abscess ECCO virtually adapted this list calling it “activity grading” (J Crohns Colitis. 2010 Feb;4(1):7-27) There are 2 small nuances: 1. Severity is defined by ECCO as mild, moderate or severe (rather then mild-to-moderate, moderate-to-severe or severe/fulminant as in ACG) 2. CRP suggested as co-parameter Posted onJanuary 27, 2021 9:18 am

Posted onJanuary 27, 2021 8:53 am

נייר עמדה HPV Posted onJanuary 27, 2021 8:40 am

I suggest that the vaad consider a committee of the several (many?) gastroenterology managers who are not departmental or unit heads at hospitals, but are community-based. Much of Gastro including most ( I guess) endoscopy is performed outside of hospitals, and together we might establish better quality standards and ways to implement these. Thank you Yishai Lachter - Head of Gastro for Meuhedet Northern Region ( 14 GIs). Posted onJanuary 27, 2021 8:37 am

******************* Day 2 ********************Posted onJanuary 27, 2021 7:50 am

מה הסיבה לשימוש בפלטפורמת אם-אם-אקס אם התרופה ממילא פועלת סיסטמית? Posted onJanuary 26, 2021 2:17 pm

no soundPosted onJanuary 26, 2021 1:39 pm

Posted onJanuary 26, 2021 1:38 pm

בכמה חודשים מאריך המשלב החדש את ה- overall survival?Posted onJanuary 26, 2021 12:25 pm

Posted onJanuary 26, 2021 12:25 pm

Presentation of VCE+ Different results if you take patients with abdominal pain and IDA+ did you have only asymptomatic patients+ question uo AntonPosted onJanuary 26, 2021 11:23 am

Important if IDA patient has abdominal pain also+ inPosted onJanuary 26, 2021 11:21 am

Posted onJanuary 26, 2021 11:20 am

Posted onJanuary 26, 2021 9:52 am

Thank you for the great talk. How do you expect to achieve disease clearance- combination therapies, distant treatment and monitoring or by multidisciplinary team approach?Posted onJanuary 26, 2021 9:51 am

Posted onJanuary 26, 2021 9:49 am

Posted onJanuary 26, 2021 9:28 am

Posted onJanuary 26, 2021 9:21 am

Posted onJanuary 26, 2021 9:16 am

test Posted onJanuary 26, 2021 9:12 am

Posted onJanuary 26, 2021 9:04 am

Congrats on the achievements!!! How come we have a vaccine for Covid 19 and not for HCV? Posted onJanuary 26, 2021 8:59 am

Test.Posted onJanuary 26, 2021 8:55 am

Posted onJanuary 26, 2021 8:38 am

Posted onJanuary 26, 2021 8:25 am

Posted onJanuary 26, 2021 8:23 am

Posted onJanuary 26, 2021 8:23 am

Posted onJanuary 26, 2021 8:19 am

Posted onJanuary 26, 2021 8:19 am

Posted onJanuary 26, 2021 8:08 am

Posted onJanuary 26, 2021 8:04 am

Test 321Posted onJanuary 25, 2021 9:51 pm

Test-APosted onJanuary 22, 2021 1:11 pm

Hall A Are you ready?Posted onJanuary 22, 2021 12:50 pm